Canakinumab for anakinra-intolerant Schnitzler syndrome
Kolivras A, et al.
J Dermatol Treat · 2023
Grade Ccase reportn=1
Key Findings
- ●Rapid improvement after first canakinumab dose
- ●After failure of colchicine, prednisone, methotrexate, dapsone
Referenced in (1 disease)
ID: manual-a-2023-canakinumab-for-anakinraintolerant